GLP-1 medications can contribute to dehydration, especially if you experience vomiting or diarrhea
Sodium Imbalance in Patients with Acquired HO and Central Diabetes Insipidus Inform patients with diabetes insipidus and their caregivers to contact their healthcare provider if changes in fluid intake or urine output or other signs of dehydration, mental status changes (e.g., confusion, lethargy), or significant nausea and vomiting occur which may require adjustments in concomitant therapies during treatment with IMCIVREE [see Warnings and Precautions (5.6)]
These follow-up visits allow your provider to administer your GLP-1 injections while discussing your progress, monitoring your weight loss, and adjusting dosage as needed
Am J Clin Nutr, 77 (5), 1255-60
Ozempic (semaglutide) is a GLP-1 receptor agonist that produces significant appetite suppression and slows gastric emptying, resulting in substantial caloric deficit-driven weight loss
Please consult your healthcare provider regarding personal health decisions, including any questions about alcohol consumption and medication interactions.
